Clinical Trials Related to HER2-positive Breast Cancer

Related studies linked through entity extraction aliases.

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

Status: RECRUITING
Phase: PHASE3

This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

HER2 Vaccine for Locally Advanced Breast Cancer

Status: RECRUITING
Phase: PHASE1

Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients

Status: RECRUITING
Phase: NA

A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Status: RECRUITING
Phase: PHASE2/PHASE3

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Status: TERMINATED
Phase: PHASE2

Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan

Status: COMPLETED
Phase: N/A

Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

Status: RECRUITING
Phase: PHASE2

A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

Status: RECRUITING
Phase: PHASE3

Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients

Status: ACTIVE_NOT_RECRUITING
Phase: NA

Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC

Status: RECRUITING
Phase: N/A

NearWave Optical Molecular Monitoring

Status: RECRUITING
Phase: NA

Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer

Status: RECRUITING
Phase: N/A

Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients

Status: RECRUITING
Phase: N/A

Pyrotinib in HER2-positive Early Breast Cancer

Status: NOT_YET_RECRUITING
Phase: NA

Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

Status: RECRUITING
Phase: N/A

Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

Status: RECRUITING
Phase: N/A

De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients

Status: RECRUITING
Phase: N/A

Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

Status: RECRUITING
Phase: N/A